Darifenacin - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (5)Enzymes (2)

Targets (5)Enzymes (2)Biointeractions (8)

Identification

Name

Darifenacin

Accession Number

DB00496 (APRD00903)

Type

Small Molecule

Groups

Approved, Investigational

Description

Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence.

Darifenacin works by blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. It thereby decreases the urgency to urinate. It should not be used in people with urinary retention.

It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

(S)-1-(2-(2,3-dihydro-5-Benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide

Darifenacin

Darifenacina

Darifénacine

Darifenacinum

External IDs

UK 88525 / UK 88525-04

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Darifenacin Hydrobromide	CR02EYQ8GV	133099-07-7	UQAVIASOPREUIT-VQIWEWKSSA-N	Details

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Darifenacin	Tablet, extended release	15 mg/1	Oral	Actavis Pharma Company	2016-03-15	Not applicable	US
Darifenacin	Tablet, extended release	7.5 mg/1	Oral	Actavis Pharma Company	2016-03-15	Not applicable	US
Enablex	Tablet, extended release	15 mg	Oral	Merus Labs Luxco S. A R.L.	2006-04-06	Not applicable	Canada
Enablex	Tablet, extended release	7.5 mg/1	Oral	Warner Chilcott	2004-12-22	Not applicable	US
Enablex	Tablet, extended release	15 mg/1	Oral	Physicians Total Care, Inc.	2005-07-20	Not applicable	US
Enablex	Tablet, extended release	15 mg/1	Oral	Warner Chilcott	2004-12-22	Not applicable	US
Enablex	Tablet, extended release	7.5 mg/1	Oral	Physicians Total Care, Inc.	2006-11-06	Not applicable	US
Enablex	Tablet, extended release	7.5 mg	Oral	Merus Labs Luxco S. A R.L.	2006-04-06	Not applicable	Canada
Enablex	Tablet, extended release	15 mg/1	Oral	Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc	2012-03-05	Not applicable	US

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-darifenacin	Tablet, extended release	7.5 mg	Oral	Apotex Corporation	Not applicable	Not applicable	Canada
Apo-darifenacin	Tablet, extended release	15 mg	Oral	Apotex Corporation	Not applicable	Not applicable	Canada
Darifenacin	Tablet, extended release	7.5 mg/1	Oral	Jubilant Cadista Pharmaceuticals Inc.	2016-10-12	Not applicable	US
Darifenacin	Tablet, extended release	15 mg/1	Oral	Torrent Pharmaceuticals Limited	2016-11-18	Not applicable	US
Darifenacin	Tablet, extended release	7.5 mg/1	Oral	Cipla Limited	2016-09-01	Not applicable	US
Darifenacin	Tablet, extended release	15 mg/1	Oral	Jubilant Cadista Pharmaceuticals Inc.	2016-10-12	Not applicable	US
Darifenacin	Tablet, film coated, extended release	7.5 mg/1	Oral	Aurobindo Pharma	2016-09-19	Not applicable	US
Darifenacin	Tablet, extended release	15 mg/1	Oral	Cipla Limited	2016-09-01	Not applicable	US
Darifenacin	Tablet, extended release	7.5 mg/1	Oral	Torrent Pharmaceuticals Limited	2016-11-18	Not applicable	US
Darifenacin	Tablet, film coated, extended release	15 mg/1	Oral	Aurobindo Pharma	2016-09-19	Not applicable	US
Darifenacin Hydrobromide Extended-release	Tablet, extended release	7.5 mg/1	Oral	Av Kare, Inc.	2017-01-09	Not applicable	US
Darifenacin Hydrobromide Extended-release	Tablet, extended release	7.5 mg/1	Oral	Par Pharmaceutical	2016-03-15	Not applicable	US
Darifenacin Hydrobromide Extended-release	Tablet, extended release	15 mg/1	Oral	Av Kare, Inc.	2017-01-09	Not applicable	US
Darifenacin Hydrobromide Extended-release	Tablet, extended release	15 mg/1	Oral	Par Pharmaceutical	2016-03-15	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Emselex	Novartis
Xelena	Dr. Reddy's

Brand mixtures

Not Available

Categories

UNII

APG9819VLM

CAS number

133099-04-4

Weight

Average: 426.55
Monoisotopic: 426.230728214

Chemical Formula

C₂₈H₃₀N₂O₂

InChI Key

HXGBXQDTNZMWGS-RUZDIDTESA-N

InChI

InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1

IUPAC Name

2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide

SMILES

NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

Structured Indications

Over Active Bladder

Pharmacodynamics

Darifenacin is a competitive muscarinic receptor antagonist. In vitro studies using human recombinant muscarinic receptor subtypes show that darifenacin has greater affinity for the M3 receptor than for the other known muscarinic receptors (9 and 12-fold greater affinity for M3 compared to M1 and M5, respectively, and 59-fold greater affinity for M3 compared to both M2 and M4). Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of the urinary bladder smooth muscle and stimulation of salivary secretion. Adverse drug effects such as dry mouth, constipation and abnormal vision may be mediated through effects on M3 receptors in these organs.

Mechanism of action

Darifenacin selectively antagonizes the muscarinic M3 receptor. M3 receptors are involved in contraction of human bladder and gastrointestinal smooth muscle, saliva production, and iris sphincter function.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Muscarinic acetylcholine receptor M3	Protein	yes	antagonist	Human	P20309	details
Muscarinic acetylcholine receptor M1	Protein	unknown	antagonist	Human	P11229	details
Muscarinic acetylcholine receptor M2	Protein	unknown	antagonist	Human	P08172	details
Muscarinic acetylcholine receptor M4	Protein	unknown	antagonist	Human	P08173	details
Muscarinic acetylcholine receptor M5	Protein	unknown	antagonist	Human	P08912	details

Absorption

The mean oral bioavailability at steady state is estimated to be 15% and 19% for 7.5 mg and 15 mg tablets, respectively.

Volume of distribution

163 L

Protein binding

Darifenacin is approximately 98% bound to plasma proteins (primarily to alpha-1-acid-glycoprotein).

Metabolism

Hepatic. Primarily mediated by the cytochrome P450 enzymes CYP2D6 and CYP3A4.

Route of elimination

Not Available

Half life

The elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.

Clearance

40 L/h [extensive metabolizers]
32 L/h [poor metabolizers]

Toxicity

Overdosage can potentially result in severe central anticholinergic effects.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
1,10-Phenanthroline	The therapeutic efficacy of Darifenacin can be decreased when used in combination with 1,10-Phenanthroline.	Experimental
4-Methoxyamphetamine	The metabolism of 4-Methoxyamphetamine can be decreased when combined with Darifenacin.	Experimental, Illicit
Abiraterone	The serum concentration of Darifenacin can be increased when it is combined with Abiraterone.	Approved
Acetaminophen	The metabolism of Acetaminophen can be decreased when combined with Darifenacin.	Approved
Acetylcholine	The metabolism of Acetylcholine can be decreased when combined with Darifenacin.	Approved
Aclidinium	Aclidinium may increase the anticholinergic activities of Darifenacin.	Approved
Ajmaline	The metabolism of Ajmaline can be decreased when combined with Darifenacin.	Approved
Alfentanil	The risk or severity of adverse effects can be increased when Darifenacin is combined with Alfentanil.	Approved, Illicit
Almotriptan	The metabolism of Almotriptan can be decreased when combined with Darifenacin.	Approved, Investigational
Alogliptin	The metabolism of Alogliptin can be decreased when combined with Darifenacin.	Approved
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Darifenacin is combined with Alphacetylmethadol.	Experimental, Illicit
Alprenolol	The metabolism of Alprenolol can be decreased when combined with Darifenacin.	Approved, Withdrawn
Ambenonium	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Ambenonium.	Approved
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Darifenacin.	Approved, Withdrawn
Amiodarone	The metabolism of Darifenacin can be decreased when combined with Amiodarone.	Approved, Investigational
Amitriptyline	The metabolism of Amitriptyline can be decreased when combined with Darifenacin.	Approved
Amoxapine	The metabolism of Amoxapine can be decreased when combined with Darifenacin.	Approved
Amphetamine	The metabolism of Amphetamine can be decreased when combined with Darifenacin.	Approved, Illicit
Amprenavir	The metabolism of Amprenavir can be decreased when combined with Darifenacin.	Approved
Amsacrine	The metabolism of Amsacrine can be decreased when combined with Darifenacin.	Approved
Anisotropine Methylbromide	The risk or severity of adverse effects can be increased when Darifenacin is combined with Anisotropine Methylbromide.	Approved
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Darifenacin.	Approved
Aprepitant	The serum concentration of Darifenacin can be increased when it is combined with Aprepitant.	Approved, Investigational
Aprindine	The metabolism of Aprindine can be decreased when combined with Darifenacin.	Approved
Arformoterol	The metabolism of Arformoterol can be decreased when combined with Darifenacin.	Approved, Investigational
Aripiprazole	The serum concentration of Aripiprazole can be increased when it is combined with Darifenacin.	Approved, Investigational
Artemether	The metabolism of Artemether can be decreased when combined with Darifenacin.	Approved
Astemizole	The metabolism of Astemizole can be decreased when combined with Darifenacin.	Approved, Withdrawn
Atazanavir	The metabolism of Darifenacin can be decreased when combined with Atazanavir.	Approved, Investigational
Atomoxetine	The metabolism of Darifenacin can be decreased when combined with Atomoxetine.	Approved
Atracurium besylate	The risk or severity of adverse effects can be increased when Darifenacin is combined with Atracurium besylate.	Approved
Atropine	The risk or severity of adverse effects can be increased when Darifenacin is combined with Atropine.	Approved, Vet Approved
Azelastine	The metabolism of Azelastine can be decreased when combined with Darifenacin.	Approved
Benactyzine	The risk or severity of adverse effects can be increased when Darifenacin is combined with Benactyzine.	Withdrawn
Bendroflumethiazide	The serum concentration of Bendroflumethiazide can be increased when it is combined with Darifenacin.	Approved
Benzatropine	The risk or severity of adverse effects can be increased when Benzatropine is combined with Darifenacin.	Approved
Benzyl alcohol	The metabolism of Benzyl alcohol can be decreased when combined with Darifenacin.	Approved
Bepridil	The metabolism of Bepridil can be decreased when combined with Darifenacin.	Approved, Withdrawn
Betaxolol	The metabolism of Darifenacin can be decreased when combined with Betaxolol.	Approved
Bexarotene	The serum concentration of Darifenacin can be decreased when it is combined with Bexarotene.	Approved, Investigational
Bezitramide	The risk or severity of adverse effects can be increased when Darifenacin is combined with Bezitramide.	Experimental, Illicit, Withdrawn
Biperiden	The risk or severity of adverse effects can be increased when Darifenacin is combined with Biperiden.	Approved
Bisoprolol	The metabolism of Bisoprolol can be decreased when combined with Darifenacin.	Approved
Boceprevir	The metabolism of Darifenacin can be decreased when combined with Boceprevir.	Approved, Investigational
Bortezomib	The metabolism of Darifenacin can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Darifenacin can be decreased when it is combined with Bosentan.	Approved, Investigational
Botulinum Toxin Type A	Darifenacin may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved, Investigational
Botulinum Toxin Type B	Darifenacin may increase the anticholinergic activities of Botulinum Toxin Type B.	Approved
Brexpiprazole	The serum concentration of Brexpiprazole can be increased when it is combined with Darifenacin.	Approved
Brompheniramine	The metabolism of Brompheniramine can be decreased when combined with Darifenacin.	Approved
Bufuralol	The metabolism of Bufuralol can be decreased when combined with Darifenacin.	Experimental, Investigational
Bupivacaine	The metabolism of Bupivacaine can be decreased when combined with Darifenacin.	Approved, Investigational
Buprenorphine	The metabolism of Buprenorphine can be decreased when combined with Darifenacin.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The metabolism of Darifenacin can be decreased when combined with Bupropion.	Approved
Buspirone	The metabolism of Buspirone can be decreased when combined with Darifenacin.	Approved, Investigational
Butorphanol	The risk or severity of adverse effects can be increased when Darifenacin is combined with Butorphanol.	Approved, Illicit, Vet Approved
Caffeine	The metabolism of Caffeine can be decreased when combined with Darifenacin.	Approved
Captopril	The metabolism of Captopril can be decreased when combined with Darifenacin.	Approved
Carbamazepine	The metabolism of Darifenacin can be increased when combined with Carbamazepine.	Approved, Investigational
Carfentanil	The risk or severity of adverse effects can be increased when Darifenacin is combined with Carfentanil.	Illicit, Vet Approved
Cariprazine	The metabolism of Cariprazine can be decreased when combined with Darifenacin.	Approved
Carteolol	The metabolism of Carteolol can be decreased when combined with Darifenacin.	Approved
Carvedilol	The metabolism of Carvedilol can be decreased when combined with Darifenacin.	Approved, Investigational
Celecoxib	The metabolism of Darifenacin can be decreased when combined with Celecoxib.	Approved, Investigational
Cephalexin	The metabolism of Cephalexin can be decreased when combined with Darifenacin.	Approved, Vet Approved
Ceritinib	The serum concentration of Darifenacin can be increased when it is combined with Ceritinib.	Approved
Cevimeline	The metabolism of Cevimeline can be decreased when combined with Darifenacin.	Approved
Chlordiazepoxide	The metabolism of Chlordiazepoxide can be decreased when combined with Darifenacin.	Approved, Illicit
Chloroquine	The metabolism of Chloroquine can be decreased when combined with Darifenacin.	Approved, Vet Approved
Chlorothiazide	The serum concentration of Chlorothiazide can be increased when it is combined with Darifenacin.	Approved, Vet Approved
Chlorphenamine	The metabolism of Chlorphenamine can be decreased when combined with Darifenacin.	Approved
Chlorphenoxamine	The risk or severity of adverse effects can be increased when Darifenacin is combined with Chlorphenoxamine.	Withdrawn
Chlorpromazine	The metabolism of Darifenacin can be decreased when combined with Chlorpromazine.	Approved, Vet Approved
Chlorthalidone	The serum concentration of Chlorthalidone can be increased when it is combined with Darifenacin.	Approved
Chlorzoxazone	The metabolism of Chlorzoxazone can be decreased when combined with Darifenacin.	Approved
Cholecalciferol	The metabolism of Darifenacin can be decreased when combined with Cholecalciferol.	Approved, Nutraceutical
Cilostazol	The metabolism of Cilostazol can be decreased when combined with Darifenacin.	Approved
Cimetidine	The metabolism of Darifenacin can be decreased when combined with Cimetidine.	Approved
Cimetropium	Darifenacin may increase the anticholinergic activities of Cimetropium.	Experimental
Cinacalcet	The metabolism of Darifenacin can be decreased when combined with Cinacalcet.	Approved
Cinnarizine	The metabolism of Cinnarizine can be decreased when combined with Darifenacin.	Approved
Citalopram	The metabolism of Darifenacin can be decreased when combined with Citalopram.	Approved
Clarithromycin	The metabolism of Darifenacin can be decreased when combined with Clarithromycin.	Approved
Clemastine	The metabolism of Darifenacin can be decreased when combined with Clemastine.	Approved
Clevidipine	The metabolism of Clevidipine can be decreased when combined with Darifenacin.	Approved
Clobazam	The metabolism of Darifenacin can be decreased when combined with Clobazam.	Approved, Illicit
Clomipramine	The metabolism of Clomipramine can be decreased when combined with Darifenacin.	Approved, Vet Approved
Clonidine	The metabolism of Clonidine can be decreased when combined with Darifenacin.	Approved
Clotrimazole	The metabolism of Darifenacin can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The metabolism of Darifenacin can be decreased when combined with Clozapine.	Approved
Cobicistat	The serum concentration of Darifenacin can be increased when it is combined with Cobicistat.	Approved
Cocaine	The metabolism of Darifenacin can be decreased when combined with Cocaine.	Approved, Illicit
Codeine	The therapeutic efficacy of Codeine can be decreased when used in combination with Darifenacin.	Approved, Illicit
Conivaptan	The serum concentration of Darifenacin can be increased when it is combined with Conivaptan.	Approved, Investigational
Crizotinib	The metabolism of Darifenacin can be decreased when combined with Crizotinib.	Approved
Cyclobenzaprine	The metabolism of Cyclobenzaprine can be decreased when combined with Darifenacin.	Approved
Cyclopentolate	The risk or severity of adverse effects can be increased when Darifenacin is combined with Cyclopentolate.	Approved
Cyclophosphamide	The metabolism of Cyclophosphamide can be decreased when combined with Darifenacin.	Approved, Investigational
Cyclosporine	The metabolism of Darifenacin can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Dabrafenib	The serum concentration of Darifenacin can be decreased when it is combined with Dabrafenib.	Approved
Dapagliflozin	The metabolism of Dapagliflozin can be decreased when combined with Darifenacin.	Approved
Darunavir	The serum concentration of Darifenacin can be increased when it is combined with Darunavir.	Approved
Dasabuvir	The metabolism of Dasabuvir can be decreased when combined with Darifenacin.	Approved
Dasatinib	The serum concentration of Darifenacin can be increased when it is combined with Dasatinib.	Approved, Investigational
Debrisoquin	The metabolism of Debrisoquin can be decreased when combined with Darifenacin.	Approved
Decamethonium	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Decamethonium.	Approved
Deferasirox	The serum concentration of Darifenacin can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The metabolism of Darifenacin can be decreased when combined with Delavirdine.	Approved
Demecarium	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Demecarium.	Approved
Desipramine	The metabolism of Desipramine can be decreased when combined with Darifenacin.	Approved
Desloratadine	The risk or severity of adverse effects can be increased when Darifenacin is combined with Desloratadine.	Approved, Investigational
Dexamethasone	The serum concentration of Darifenacin can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexetimide	The risk or severity of adverse effects can be increased when Darifenacin is combined with Dexetimide.	Withdrawn
Dexfenfluramine	The metabolism of Dexfenfluramine can be decreased when combined with Darifenacin.	Approved, Illicit, Withdrawn
Dexmethylphenidate	The metabolism of Dexmethylphenidate can be decreased when combined with Darifenacin.	Approved
Dextroamphetamine	The metabolism of Dextroamphetamine can be decreased when combined with Darifenacin.	Approved, Illicit
Dextromethorphan	The metabolism of Dextromethorphan can be decreased when combined with Darifenacin.	Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Darifenacin is combined with Dextromoramide.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Darifenacin is combined with Dextropropoxyphene.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Darifenacin is combined with Dezocine.	Approved
Dicyclomine	The risk or severity of adverse effects can be increased when Darifenacin is combined with Dicyclomine.	Approved
Dihydrocodeine	The metabolism of Dihydrocodeine can be decreased when combined with Darifenacin.	Approved, Illicit
Dihydroergotamine	The metabolism of Darifenacin can be decreased when combined with Dihydroergotamine.	Approved
Dihydroetorphine	The risk or severity of adverse effects can be increased when Darifenacin is combined with Dihydroetorphine.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Darifenacin is combined with Dihydromorphine.	Experimental, Illicit
Diltiazem	The metabolism of Darifenacin can be decreased when combined with Diltiazem.	Approved
Diphenhydramine	The metabolism of Diphenhydramine can be decreased when combined with Darifenacin.	Approved
Diphenoxylate	The risk or severity of adverse effects can be increased when Darifenacin is combined with Diphenoxylate.	Approved, Illicit
Dolasetron	The metabolism of Dolasetron can be decreased when combined with Darifenacin.	Approved
Domperidone	The metabolism of Domperidone can be decreased when combined with Darifenacin.	Approved, Investigational, Vet Approved
Donepezil	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Donepezil.	Approved
Dopamine	The metabolism of Dopamine can be decreased when combined with Darifenacin.	Approved
Doxazosin	The metabolism of Doxazosin can be decreased when combined with Darifenacin.	Approved
Doxepin	The metabolism of Doxepin can be decreased when combined with Darifenacin.	Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Darifenacin.	Approved, Investigational
Doxorubicin	The metabolism of Doxorubicin can be decreased when combined with Darifenacin.	Approved, Investigational
Doxycycline	The metabolism of Darifenacin can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronabinol	Darifenacin may increase the tachycardic activities of Dronabinol.	Approved, Illicit
Dronedarone	The metabolism of Darifenacin can be decreased when combined with Dronedarone.	Approved
Duloxetine	The metabolism of Darifenacin can be decreased when combined with Duloxetine.	Approved
Echothiophate	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Echothiophate.	Approved
Edrophonium	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Edrophonium.	Approved
Efavirenz	The serum concentration of Darifenacin can be decreased when it is combined with Efavirenz.	Approved, Investigational
Eletriptan	The metabolism of Eletriptan can be decreased when combined with Darifenacin.	Approved, Investigational
Eliglustat	The serum concentration of Eliglustat can be increased when it is combined with Darifenacin.	Approved
Eluxadoline	Darifenacin may increase the constipating activities of Eluxadoline.	Approved
Encainide	The metabolism of Encainide can be decreased when combined with Darifenacin.	Approved, Withdrawn
Enclomiphene	The metabolism of Enclomiphene can be decreased when combined with Darifenacin.	Investigational
Enzalutamide	The serum concentration of Darifenacin can be decreased when it is combined with Enzalutamide.	Approved
Epinastine	The metabolism of Epinastine can be decreased when combined with Darifenacin.	Approved, Investigational
Erlotinib	The metabolism of Erlotinib can be decreased when combined with Darifenacin.	Approved, Investigational
Erythromycin	The metabolism of Darifenacin can be decreased when combined with Erythromycin.	Approved, Vet Approved
Escitalopram	The metabolism of Escitalopram can be decreased when combined with Darifenacin.	Approved, Investigational
Eslicarbazepine acetate	The serum concentration of Darifenacin can be decreased when it is combined with Eslicarbazepine acetate.	Approved
Esmirtazapine	The metabolism of Esmirtazapine can be decreased when combined with Darifenacin.	Investigational
Ethopropazine	The risk or severity of adverse effects can be increased when Ethopropazine is combined with Darifenacin.	Approved
Ethylmorphine	The metabolism of Ethylmorphine can be decreased when combined with Darifenacin.	Approved, Illicit
Etoricoxib	The metabolism of Etoricoxib can be decreased when combined with Darifenacin.	Approved, Investigational
Etorphine	The risk or severity of adverse effects can be increased when Darifenacin is combined with Etorphine.	Illicit, Vet Approved
Etravirine	The serum concentration of Darifenacin can be decreased when it is combined with Etravirine.	Approved
Fentanyl	The risk or severity of adverse effects can be increased when Darifenacin is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Darifenacin.	Approved
Fingolimod	The metabolism of Fingolimod can be decreased when combined with Darifenacin.	Approved, Investigational
Flecainide	The metabolism of Flecainide can be decreased when combined with Darifenacin.	Approved, Withdrawn
Fluconazole	The metabolism of Darifenacin can be decreased when combined with Fluconazole.	Approved
Flunarizine	The metabolism of Flunarizine can be decreased when combined with Darifenacin.	Approved
Fluoxetine	The metabolism of Darifenacin can be decreased when combined with Fluoxetine.	Approved, Vet Approved
Fluphenazine	The metabolism of Fluphenazine can be decreased when combined with Darifenacin.	Approved
Fluvastatin	The metabolism of Fluvastatin can be decreased when combined with Darifenacin.	Approved
Fluvoxamine	The metabolism of Darifenacin can be decreased when combined with Fluvoxamine.	Approved, Investigational
Formoterol	The metabolism of Formoterol can be decreased when combined with Darifenacin.	Approved, Investigational
Fosamprenavir	The metabolism of Darifenacin can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Darifenacin can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The metabolism of Darifenacin can be increased when combined with Fosphenytoin.	Approved
Fusidic Acid	The serum concentration of Darifenacin can be increased when it is combined with Fusidic Acid.	Approved
Galantamine	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Galantamine.	Approved
Gallamine Triethiodide	The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Darifenacin.	Approved
Gefitinib	The metabolism of Gefitinib can be decreased when combined with Darifenacin.	Approved, Investigational
Ginkgo biloba	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Ginkgo biloba.	Approved, Nutraceutical
Glucagon recombinant	The risk or severity of adverse effects can be increased when Darifenacin is combined with Glucagon recombinant.	Approved
Glycopyrronium	Darifenacin may increase the anticholinergic activities of Glycopyrronium.	Approved, Investigational, Vet Approved
Granisetron	The metabolism of Granisetron can be decreased when combined with Darifenacin.	Approved, Investigational
Halofantrine	The metabolism of Halofantrine can be decreased when combined with Darifenacin.	Approved
Haloperidol	The metabolism of Haloperidol can be decreased when combined with Darifenacin.	Approved
Halothane	The metabolism of Halothane can be decreased when combined with Darifenacin.	Approved, Vet Approved
Heroin	The risk or severity of adverse effects can be increased when Darifenacin is combined with Heroin.	Approved, Illicit
Hexamethonium	The risk or severity of adverse effects can be increased when Darifenacin is combined with Hexamethonium.	Experimental
Huperzine A	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Huperzine A.	Investigational
Hydrochlorothiazide	The serum concentration of Hydrochlorothiazide can be increased when it is combined with Darifenacin.	Approved, Vet Approved
Hydrocodone	The metabolism of Hydrocodone can be decreased when combined with Darifenacin.	Approved, Illicit
Hydroflumethiazide	The serum concentration of Hydroflumethiazide can be increased when it is combined with Darifenacin.	Approved
Hydromorphone	The metabolism of Hydromorphone can be decreased when combined with Darifenacin.	Approved, Illicit
Hyoscyamine	The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Darifenacin.	Approved
Ibrutinib	The metabolism of Ibrutinib can be decreased when combined with Darifenacin.	Approved
Idarubicin	The metabolism of Idarubicin can be decreased when combined with Darifenacin.	Approved
Idelalisib	The serum concentration of Darifenacin can be increased when it is combined with Idelalisib.	Approved
Iloperidone	The metabolism of Iloperidone can be decreased when combined with Darifenacin.	Approved
Imatinib	The metabolism of Darifenacin can be decreased when combined with Imatinib.	Approved
Imipramine	The metabolism of Darifenacin can be decreased when combined with Imipramine.	Approved
Indapamide	The serum concentration of Indapamide can be increased when it is combined with Darifenacin.	Approved
Indinavir	The metabolism of Darifenacin can be decreased when combined with Indinavir.	Approved
Ipratropium bromide	The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Darifenacin.	Approved
Isavuconazonium	The metabolism of Darifenacin can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isoflurophate	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Isoflurophate.	Approved, Withdrawn
Isoniazid	The metabolism of Darifenacin can be decreased when combined with Isoniazid.	Approved
Isradipine	The metabolism of Darifenacin can be decreased when combined with Isradipine.	Approved
Itopride	The therapeutic efficacy of Itopride can be decreased when used in combination with Darifenacin.	Investigational
Itraconazole	The metabolism of Darifenacin can be decreased when combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Darifenacin can be increased when it is combined with Ivacaftor.	Approved
Ixazomib	The metabolism of Ixazomib can be decreased when combined with Darifenacin.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Darifenacin is combined with Ketobemidone.	Approved
Ketoconazole	The metabolism of Darifenacin can be decreased when combined with Ketoconazole.	Approved, Investigational
Labetalol	The metabolism of Labetalol can be decreased when combined with Darifenacin.	Approved
Levodopa	The metabolism of Levodopa can be decreased when combined with Darifenacin.	Approved
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Darifenacin is combined with Levomethadyl Acetate.	Approved
Levomilnacipran	The metabolism of Levomilnacipran can be decreased when combined with Darifenacin.	Approved
Levorphanol	The risk or severity of adverse effects can be increased when Darifenacin is combined with Levorphanol.	Approved
Lidocaine	The metabolism of Lidocaine can be decreased when combined with Darifenacin.	Approved, Vet Approved
Lisuride	The metabolism of Lisuride can be decreased when combined with Darifenacin.	Approved
Lofentanil	The risk or severity of adverse effects can be increased when Darifenacin is combined with Lofentanil.	Illicit
Lomustine	The metabolism of Lomustine can be decreased when combined with Darifenacin.	Approved
Loperamide	The metabolism of Loperamide can be decreased when combined with Darifenacin.	Approved
Lopinavir	The metabolism of Darifenacin can be decreased when combined with Lopinavir.	Approved
Loratadine	The metabolism of Loratadine can be decreased when combined with Darifenacin.	Approved
Lorcaserin	The metabolism of Lorcaserin can be decreased when combined with Darifenacin.	Approved
Lovastatin	The metabolism of Darifenacin can be decreased when combined with Lovastatin.	Approved, Investigational
Luliconazole	The serum concentration of Darifenacin can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The metabolism of Darifenacin can be increased when combined with Lumacaftor.	Approved
Lumefantrine	The metabolism of Darifenacin can be decreased when combined with Lumefantrine.	Approved
Malathion	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Malathion.	Approved, Investigational
Maprotiline	The metabolism of Maprotiline can be decreased when combined with Darifenacin.	Approved
Mecamylamine	The risk or severity of adverse effects can be increased when Darifenacin is combined with Mecamylamine.	Approved
Mefloquine	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Mefloquine.	Approved
Memantine	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Memantine.	Approved, Investigational
Mephenytoin	The metabolism of Mephenytoin can be decreased when combined with Darifenacin.	Investigational, Withdrawn
Mequitazine	The metabolism of Mequitazine can be decreased when combined with Darifenacin.	Approved
Mesoridazine	The metabolism of Mesoridazine can be decreased when combined with Darifenacin.	Approved
Methadone	The metabolism of Darifenacin can be decreased when combined with Methadone.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Darifenacin is combined with Methadyl Acetate.	Approved, Illicit
Methamphetamine	The metabolism of Methamphetamine can be decreased when combined with Darifenacin.	Approved, Illicit
Methantheline	The risk or severity of adverse effects can be increased when Darifenacin is combined with Methantheline.	Approved
Methotrimeprazine	The metabolism of Darifenacin can be decreased when combined with Methotrimeprazine.	Approved
Methoxyflurane	The metabolism of Methoxyflurane can be decreased when combined with Darifenacin.	Approved, Vet Approved
Methyclothiazide	The serum concentration of Methyclothiazide can be increased when it is combined with Darifenacin.	Approved
Methylphenidate	The metabolism of Methylphenidate can be decreased when combined with Darifenacin.	Approved, Investigational
Methyprylon	The metabolism of Methyprylon can be decreased when combined with Darifenacin.	Approved, Illicit, Withdrawn
Metixene	The risk or severity of adverse effects can be increased when Darifenacin is combined with Metixene.	Approved
Metoclopramide	The metabolism of Metoclopramide can be decreased when combined with Darifenacin.	Approved, Investigational
Metolazone	The serum concentration of Metolazone can be increased when it is combined with Darifenacin.	Approved
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Darifenacin.	Approved, Investigational
Mexiletine	The metabolism of Mexiletine can be decreased when combined with Darifenacin.	Approved
Mianserin	Mianserin may increase the anticholinergic activities of Darifenacin.	Approved
Mifepristone	The serum concentration of Darifenacin can be increased when it is combined with Mifepristone.	Approved, Investigational
Minaprine	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Minaprine.	Approved
Mirabegron	The risk or severity of adverse effects can be increased when Darifenacin is combined with Mirabegron.	Approved
Mirtazapine	The metabolism of Mirtazapine can be decreased when combined with Darifenacin.	Approved
Mitotane	The serum concentration of Darifenacin can be decreased when it is combined with Mitotane.	Approved
Moclobemide	The metabolism of Moclobemide can be decreased when combined with Darifenacin.	Approved
Modafinil	The serum concentration of Darifenacin can be decreased when it is combined with Modafinil.	Approved, Investigational
Morphine	The metabolism of Morphine can be decreased when combined with Darifenacin.	Approved, Investigational
Nabilone	Darifenacin may increase the tachycardic activities of Nabilone.	Approved, Investigational
Nafcillin	The serum concentration of Darifenacin can be decreased when it is combined with Nafcillin.	Approved
Nalbuphine	The risk or severity of adverse effects can be increased when Darifenacin is combined with Nalbuphine.	Approved
Nateglinide	The metabolism of Nateglinide can be decreased when combined with Darifenacin.	Approved, Investigational
Nebivolol	The serum concentration of Nebivolol can be increased when it is combined with Darifenacin.	Approved, Investigational
Nefazodone	The metabolism of Darifenacin can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The metabolism of Darifenacin can be decreased when combined with Nelfinavir.	Approved
Neostigmine	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Neostigmine.	Approved, Vet Approved
Netupitant	The serum concentration of Darifenacin can be increased when it is combined with Netupitant.	Approved
Nevirapine	The metabolism of Darifenacin can be increased when combined with Nevirapine.	Approved
Nicardipine	The metabolism of Nicardipine can be decreased when combined with Darifenacin.	Approved
Nicergoline	The metabolism of Nicergoline can be decreased when combined with Darifenacin.	Approved
Nicotine	The metabolism of Nicotine can be decreased when combined with Darifenacin.	Approved
Nifedipine	The metabolism of Nifedipine can be decreased when combined with Darifenacin.	Approved
Nilotinib	The metabolism of Darifenacin can be decreased when combined with Nilotinib.	Approved, Investigational
Nitrofural	The metabolism of Nitrofural can be decreased when combined with Darifenacin.	Approved, Vet Approved
Normethadone	The risk or severity of adverse effects can be increased when Darifenacin is combined with Normethadone.	Approved, Illicit
Nortriptyline	The metabolism of Nortriptyline can be decreased when combined with Darifenacin.	Approved
Olanzapine	The metabolism of Olanzapine can be decreased when combined with Darifenacin.	Approved, Investigational
Olaparib	The metabolism of Darifenacin can be decreased when combined with Olaparib.	Approved
Ondansetron	The metabolism of Ondansetron can be decreased when combined with Darifenacin.	Approved
Opium	The risk or severity of adverse effects can be increased when Darifenacin is combined with Opium.	Approved, Illicit
Orphenadrine	The risk or severity of adverse effects can be increased when Darifenacin is combined with Orphenadrine.	Approved
Osimertinib	The serum concentration of Darifenacin can be increased when it is combined with Osimertinib.	Approved
Oxybutynin	The risk or severity of adverse effects can be increased when Darifenacin is combined with Oxybutynin.	Approved, Investigational
Oxycodone	The metabolism of Oxycodone can be decreased when combined with Darifenacin.	Approved, Illicit, Investigational
Oxymorphone	The metabolism of Oxymorphone can be decreased when combined with Darifenacin.	Approved, Investigational, Vet Approved
Oxyphenonium	The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Darifenacin.	Approved
Palbociclib	The serum concentration of Darifenacin can be increased when it is combined with Palbociclib.	Approved
Palonosetron	The metabolism of Palonosetron can be decreased when combined with Darifenacin.	Approved, Investigational
Pancuronium	The risk or severity of adverse effects can be increased when Darifenacin is combined with Pancuronium.	Approved
Panobinostat	The serum concentration of Darifenacin can be increased when it is combined with Panobinostat.	Approved, Investigational
Paroxetine	The metabolism of Darifenacin can be decreased when combined with Paroxetine.	Approved, Investigational
Pazopanib	The metabolism of Pazopanib can be decreased when combined with Darifenacin.	Approved
Peginterferon alfa-2b	The serum concentration of Darifenacin can be decreased when it is combined with Peginterferon alfa-2b.	Approved
Pentamidine	The metabolism of Pentamidine can be decreased when combined with Darifenacin.	Approved
Pentazocine	The risk or severity of adverse effects can be increased when Darifenacin is combined with Pentazocine.	Approved, Vet Approved
Pentobarbital	The metabolism of Darifenacin can be increased when combined with Pentobarbital.	Approved, Vet Approved
Pentolinium	The risk or severity of adverse effects can be increased when Darifenacin is combined with Pentolinium.	Approved
Perhexiline	The metabolism of Perhexiline can be decreased when combined with Darifenacin.	Approved
Perphenazine	The metabolism of Perphenazine can be decreased when combined with Darifenacin.	Approved
Pethidine	The metabolism of Pethidine can be decreased when combined with Darifenacin.	Approved
Phenacetin	The metabolism of Phenacetin can be decreased when combined with Darifenacin.	Withdrawn
Phenformin	The metabolism of Phenformin can be decreased when combined with Darifenacin.	Approved, Withdrawn
Phenobarbital	The metabolism of Darifenacin can be increased when combined with Phenobarbital.	Approved
Phenytoin	The metabolism of Darifenacin can be increased when combined with Phenytoin.	Approved, Vet Approved
Physostigmine	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Physostigmine.	Approved
Pindolol	The metabolism of Pindolol can be decreased when combined with Darifenacin.	Approved
Pipecuronium	The risk or severity of adverse effects can be increased when Darifenacin is combined with Pipecuronium.	Approved
Piperazine	The metabolism of Piperazine can be decreased when combined with Darifenacin.	Approved, Vet Approved
Pipotiazine	The metabolism of Pipotiazine can be decreased when combined with Darifenacin.	Approved
Pirenzepine	The risk or severity of adverse effects can be increased when Darifenacin is combined with Pirenzepine.	Approved
Polythiazide	The serum concentration of Polythiazide can be increased when it is combined with Darifenacin.	Approved
Ponatinib	The metabolism of Ponatinib can be decreased when combined with Darifenacin.	Approved
Posaconazole	The metabolism of Darifenacin can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Potassium Chloride	Darifenacin may increase the ulcerogenic activities of Potassium Chloride.	Approved, Withdrawn
Pramlintide	Pramlintide may increase the anticholinergic activities of Darifenacin.	Approved, Investigational
Primidone	The metabolism of Darifenacin can be increased when combined with Primidone.	Approved, Vet Approved
Procainamide	The metabolism of Procainamide can be decreased when combined with Darifenacin.	Approved
Prochlorperazine	The metabolism of Prochlorperazine can be decreased when combined with Darifenacin.	Approved, Vet Approved
Procyclidine	The risk or severity of adverse effects can be increased when Procyclidine is combined with Darifenacin.	Approved
Progesterone	The metabolism of Progesterone can be decreased when combined with Darifenacin.	Approved, Vet Approved
Promazine	The metabolism of Darifenacin can be decreased when combined with Promazine.	Approved, Vet Approved
Promethazine	The metabolism of Promethazine can be decreased when combined with Darifenacin.	Approved
Propafenone	The serum concentration of Darifenacin can be increased when it is combined with Propafenone.	Approved
Propantheline	The risk or severity of adverse effects can be increased when Darifenacin is combined with Propantheline.	Approved
Propofol	The metabolism of Propofol can be decreased when combined with Darifenacin.	Approved, Investigational, Vet Approved
Propranolol	The metabolism of Propranolol can be decreased when combined with Darifenacin.	Approved, Investigational
Protriptyline	The metabolism of Protriptyline can be decreased when combined with Darifenacin.	Approved
Pseudoephedrine	The metabolism of Pseudoephedrine can be decreased when combined with Darifenacin.	Approved
Pyridostigmine	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Pyridostigmine.	Approved
Quetiapine	The metabolism of Quetiapine can be decreased when combined with Darifenacin.	Approved
Quinethazone	The serum concentration of Quinethazone can be increased when it is combined with Darifenacin.	Approved
Quinidine	The metabolism of Darifenacin can be decreased when combined with Quinidine.	Approved
Quinine	The metabolism of Darifenacin can be decreased when combined with Quinine.	Approved
Ramosetron	Darifenacin may increase the constipating activities of Ramosetron.	Approved
Ranitidine	The metabolism of Ranitidine can be decreased when combined with Darifenacin.	Approved
Ranolazine	The metabolism of Darifenacin can be decreased when combined with Ranolazine.	Approved, Investigational
Remifentanil	The risk or severity of adverse effects can be increased when Darifenacin is combined with Remifentanil.	Approved
Remoxipride	The metabolism of Remoxipride can be decreased when combined with Darifenacin.	Approved, Withdrawn
Rifabutin	The metabolism of Darifenacin can be increased when combined with Rifabutin.	Approved
Rifampicin	The metabolism of Darifenacin can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Darifenacin can be increased when combined with Rifapentine.	Approved
Risperidone	The metabolism of Risperidone can be decreased when combined with Darifenacin.	Approved, Investigational
Ritonavir	The metabolism of Darifenacin can be decreased when combined with Ritonavir.	Approved, Investigational
Rivastigmine	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Rivastigmine.	Approved, Investigational
Rolapitant	The metabolism of Darifenacin can be decreased when combined with Rolapitant.	Approved
Ropinirole	The metabolism of Darifenacin can be decreased when combined with Ropinirole.	Approved, Investigational
Ropivacaine	The metabolism of Ropivacaine can be decreased when combined with Darifenacin.	Approved
Rotigotine	The metabolism of Rotigotine can be decreased when combined with Darifenacin.	Approved
Saquinavir	The metabolism of Darifenacin can be decreased when combined with Saquinavir.	Approved, Investigational
Scopolamine	The risk or severity of adverse effects can be increased when Darifenacin is combined with Scopolamine.	Approved
Scopolamine butylbromide	The risk or severity of adverse effects can be increased when Darifenacin is combined with Scopolamine butylbromide.	Approved
Secretin	The therapeutic efficacy of Secretin can be decreased when used in combination with Darifenacin.	Approved, Investigational
Sertindole	The metabolism of Sertindole can be decreased when combined with Darifenacin.	Approved, Withdrawn
Sertraline	The metabolism of Sertraline can be decreased when combined with Darifenacin.	Approved
Sildenafil	The metabolism of Darifenacin can be decreased when combined with Sildenafil.	Approved, Investigational
Siltuximab	The serum concentration of Darifenacin can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Darifenacin can be increased when it is combined with Simeprevir.	Approved
Simvastatin	The metabolism of Simvastatin can be decreased when combined with Darifenacin.	Approved
Solifenacin	The risk or severity of adverse effects can be increased when Darifenacin is combined with Solifenacin.	Approved
Sparteine	The metabolism of Sparteine can be decreased when combined with Darifenacin.	Experimental
St. John's Wort	The serum concentration of Darifenacin can be decreased when it is combined with St. John's Wort.	Nutraceutical
Stiripentol	The serum concentration of Darifenacin can be increased when it is combined with Stiripentol.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Darifenacin is combined with Sufentanil.	Approved, Investigational
Sulfisoxazole	The metabolism of Darifenacin can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sulpiride	The therapeutic efficacy of Sulpiride can be decreased when used in combination with Darifenacin.	Approved
Tacrine	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Tacrine.	Withdrawn
Tamoxifen	The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Darifenacin resulting in a loss in efficacy.	Approved
Tamsulosin	The metabolism of Tamsulosin can be decreased when combined with Darifenacin.	Approved, Investigational
Tapentadol	The metabolism of Tapentadol can be decreased when combined with Darifenacin.	Approved
Tegaserod	The metabolism of Tegaserod can be decreased when combined with Darifenacin.	Investigational, Withdrawn
Telaprevir	The metabolism of Darifenacin can be decreased when combined with Telaprevir.	Withdrawn
Telithromycin	The metabolism of Darifenacin can be decreased when combined with Telithromycin.	Approved
Terbinafine	The metabolism of Darifenacin can be decreased when combined with Terbinafine.	Approved, Investigational, Vet Approved
Terfenadine	The metabolism of Terfenadine can be decreased when combined with Darifenacin.	Withdrawn
Tesmilifene	The metabolism of Tesmilifene can be decreased when combined with Darifenacin.	Investigational
Tetrabenazine	The metabolism of Tetrabenazine can be decreased when combined with Darifenacin.	Approved
Theophylline	The metabolism of Theophylline can be decreased when combined with Darifenacin.	Approved
Thioridazine	The serum concentration of Thioridazine can be increased when it is combined with Darifenacin.	Withdrawn
Ticlopidine	The metabolism of Darifenacin can be decreased when combined with Ticlopidine.	Approved
Timolol	The metabolism of Timolol can be decreased when combined with Darifenacin.	Approved
Tiotropium	Darifenacin may increase the anticholinergic activities of Tiotropium.	Approved
Tipranavir	The metabolism of Darifenacin can be decreased when combined with Tipranavir.	Approved, Investigational
Tocilizumab	The serum concentration of Darifenacin can be decreased when it is combined with Tocilizumab.	Approved
Tolterodine	The risk or severity of adverse effects can be increased when Darifenacin is combined with Tolterodine.	Approved, Investigational
Topiramate	The risk or severity of adverse effects can be increased when Darifenacin is combined with Topiramate.	Approved
Trabectedin	The metabolism of Trabectedin can be decreased when combined with Darifenacin.	Approved, Investigational
Tramadol	The therapeutic efficacy of Tramadol can be decreased when used in combination with Darifenacin.	Approved, Investigational
Tranylcypromine	The metabolism of Darifenacin can be decreased when combined with Tranylcypromine.	Approved
Trazodone	The metabolism of Trazodone can be decreased when combined with Darifenacin.	Approved, Investigational
Trichlormethiazide	The serum concentration of Trichlormethiazide can be increased when it is combined with Darifenacin.	Approved, Vet Approved
Trihexyphenidyl	The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Darifenacin.	Approved
Trimethaphan	The risk or severity of adverse effects can be increased when Darifenacin is combined with Trimethaphan.	Approved
Trimipramine	The metabolism of Trimipramine can be decreased when combined with Darifenacin.	Approved
Tropicamide	The risk or severity of adverse effects can be increased when Darifenacin is combined with Tropicamide.	Approved
Trospium	The risk or severity of adverse effects can be increased when Trospium is combined with Darifenacin.	Approved
Tubocurarine	The risk or severity of adverse effects can be increased when Darifenacin is combined with Tubocurarine.	Approved
Umeclidinium	Umeclidinium may increase the anticholinergic activities of Darifenacin.	Approved
Vecuronium	The risk or severity of adverse effects can be increased when Darifenacin is combined with Vecuronium.	Approved
Venlafaxine	The metabolism of Darifenacin can be decreased when combined with Venlafaxine.	Approved
Verapamil	The metabolism of Darifenacin can be decreased when combined with Verapamil.	Approved
Vilazodone	The metabolism of Vilazodone can be decreased when combined with Darifenacin.	Approved
Vinblastine	The metabolism of Vinblastine can be decreased when combined with Darifenacin.	Approved
Vinorelbine	The metabolism of Vinorelbine can be decreased when combined with Darifenacin.	Approved, Investigational
Voriconazole	The metabolism of Darifenacin can be decreased when combined with Voriconazole.	Approved, Investigational
Vortioxetine	The metabolism of Vortioxetine can be decreased when combined with Darifenacin.	Approved
Yohimbine	The metabolism of Yohimbine can be decreased when combined with Darifenacin.	Approved, Vet Approved
Zalcitabine	The metabolism of Zalcitabine can be decreased when combined with Darifenacin.	Approved
Ziprasidone	The metabolism of Darifenacin can be decreased when combined with Ziprasidone.	Approved
Zolpidem	The metabolism of Zolpidem can be decreased when combined with Darifenacin.	Approved
Zuclopenthixol	The metabolism of Zuclopenthixol can be decreased when combined with Darifenacin.	Approved, Investigational

Food Interactions

Take without regard to meals.

References

Synthesis Reference

Valeriano Merli, Augusto Canavesi, Paola Daverio, "Processes for preparing darifenacin hydrobromide." U.S. Patent US20070197631, issued August 23, 2007.

US20070197631

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14639
KEGG Drug	D01699
PubChem Compound	444031
PubChem Substance	46508104
ChemSpider	392054
BindingDB	50109647
ChEBI	391960
ChEMBL	CHEMBL1346
Therapeutic Targets Database	DAP001131
PharmGKB	PA164774901
Drug Product Database	17051
RxList	http://www.rxlist.com/cgi/generic3/enablex.htm
Drugs.com	http://www.drugs.com/cdi/darifenacin-extended-release-tablets.html
Wikipedia	Darifenacin

ATC Codes

G04BD10

AHFS Codes

86:12.00

PDB Entries

Not Available

FDA label

Download (394 KB)

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Treatment	Healthy Volunteers	2
1	Unknown Status	Not Available	Bioequivalency	2
2	Completed	Treatment	Healthy Volunteers	1
2	Suspended	Treatment	Neurogenic Detrusor Overactivity	1
2	Terminated	Treatment	Disseminated Sclerosis / Overactive Detrusor	1
3	Completed	Treatment	Over Active Bladder	1
3	Completed	Treatment	Overactive Bladder Syndrome	2
4	Completed	Not Available	Over Active Bladder	1
4	Completed	Not Available	Urinary Incontinence (UI)	1
4	Completed	Treatment	Healthy Volunteers	1
4	Completed	Treatment	Neurogenic Detrusor Overactivity / Spinal Cord Injuries (SCI)	1
4	Completed	Treatment	Over Active Bladder	1
4	Completed	Treatment	Overactive Bladder (OAB)	1
4	Withdrawn	Not Available	Nocturia	1
Not Available	Completed	Not Available	Over Active Bladder	1
Not Available	Completed	Treatment	Over Active Bladder / Parkinson's Disease (PD)	1
Not Available	Recruiting	Not Available	Over Active Bladder / Urinary Bladder Diseases / Urinary Bladder Overactive / Urologic Diseases	1
Not Available	Terminated	Treatment	Bladder Spasms / Over Active Bladder / Postoperative / Postoperative pain / Renal Colic / Ureteral Stent Pain	1

Pharmacoeconomics

Manufacturers

Novartis pharmaceuticals corp

Packagers

Lake Erie Medical and Surgical Supply
Murfreesboro Pharmaceutical Nursing Supply
Novartis AG
Pfizer Inc.
Physicians Total Care Inc.
Redpharm Drug

Dosage forms

Form	Route	Strength
Tablet, film coated, extended release	Oral	15 mg/1
Tablet, film coated, extended release	Oral	7.5 mg/1
Tablet, extended release	Oral	15 mg
Tablet, extended release	Oral	15 mg/1
Tablet, extended release	Oral	7.5 mg/1
Tablet, extended release	Oral	7.5 mg

Prices

Unit description	Cost	Unit
Enablex 15 mg 24 Hour tablet	5.22USD	tablet
Enablex 7.5 mg 24 Hour tablet	5.22USD	tablet
Enablex 15 mg tablet	5.02USD	tablet
Enablex 7.5 mg tablet	5.02USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
CA2230314	No	2003-06-24	2016-08-21	Canada
CA2469702	No	2010-07-06	2022-03-05	Canada
US5096890	No	1995-03-13	2015-03-13	US
US6106864	No	1996-08-21	2016-08-21	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
logP	4.5	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.000298 mg/mL	ALOGPS
logP	4.35	ALOGPS
logP	4.54	ChemAxon
logS	-6.2	ALOGPS
pKa (Strongest Acidic)	16.21	ChemAxon
pKa (Strongest Basic)	10.11	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	55.56 Å²	ChemAxon
Rotatable Bond Count	7	ChemAxon
Refractivity	128.37 m³·mol^-1	ChemAxon
Polarizability	48.54 Å³	ChemAxon
Number of Rings	5	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9966
Blood Brain Barrier	+	0.9989
Caco-2 permeable	-	0.5256
P-glycoprotein substrate	Substrate	0.6385
P-glycoprotein inhibitor I	Non-inhibitor	0.6329
P-glycoprotein inhibitor II	Inhibitor	0.5374
Renal organic cation transporter	Inhibitor	0.6441
CYP450 2C9 substrate	Non-substrate	0.8774
CYP450 2D6 substrate	Non-substrate	0.5946
CYP450 3A4 substrate	Substrate	0.6046
CYP450 1A2 substrate	Non-inhibitor	0.696
CYP450 2C9 inhibitor	Non-inhibitor	0.8253
CYP450 2D6 inhibitor	Inhibitor	0.5816
CYP450 2C19 inhibitor	Inhibitor	0.5399
CYP450 3A4 inhibitor	Inhibitor	0.5
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.6168
Ames test	Non AMES toxic	0.7145
Carcinogenicity	Non-carcinogens	0.8847
Biodegradation	Not ready biodegradable	0.9599
Rat acute toxicity	3.0008 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.907
hERG inhibition (predictor II)	Inhibitor	0.6703

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Benzenoids

Sub Class

Benzene and substituted derivatives

Direct Parent

Diphenylmethanes

Alternative Parents

Phenylacetamides / Phenethylamines / Coumarans / Aralkylamines / Alkyl aryl ethers / N-alkylpyrrolidines / Trialkylamines / Primary carboxylic acid amides / Amino acids and derivatives / Oxacyclic compounds

Substituents

Diphenylmethane / Phenylacetamide / Phenethylamine / Coumaran / Alkyl aryl ether / Aralkylamine / N-alkylpyrrolidine / Pyrrolidine / Amino acid or derivatives / Carboxamide group

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

monocarboxylic acid amide, 1-benzofurans, pyrrolidines (CHEBI:391960 )

Targets

Details

1. Muscarinic acetylcholine receptor M3

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: antagonist

General Function:: Receptor activity
Specific Function:: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:: CHRM3
Uniprot ID:: P20309
Molecular Weight:: 66127.445 Da

References

Bharucha AE, Ravi K, Zinsmeister AR: Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans. Am J Physiol Gastrointest Liver Physiol. 2010 Jul;299(1):G215-9. doi: 10.1152/ajpgi.00072.2010. Epub 2010 Apr 15. [PubMed:20395537 ]
Bozkurt TE, Sahin-Erdemli I: M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5. doi: 10.1016/j.phrs.2009.01.013. Epub 2009 Feb 5. [PubMed:19416629 ]
Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Details

2. Muscarinic acetylcholine receptor M1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: antagonist

General Function:: Phosphatidylinositol phospholipase c activity
Specific Function:: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:: CHRM1
Uniprot ID:: P11229
Molecular Weight:: 51420.375 Da

References

Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909 ]
Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. [PubMed:10374898 ]

Details

3. Muscarinic acetylcholine receptor M2

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: antagonist

General Function:: G-protein coupled acetylcholine receptor activity
Specific Function:: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:: CHRM2
Uniprot ID:: P08172
Molecular Weight:: 51714.605 Da

References

Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909 ]
Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. [PubMed:10374898 ]

Details

4. Muscarinic acetylcholine receptor M4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: antagonist

General Function:: Guanyl-nucleotide exchange factor activity
Specific Function:: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:: CHRM4
Uniprot ID:: P08173
Molecular Weight:: 53048.65 Da

References

Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909 ]
Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. [PubMed:10374898 ]

Details

5. Muscarinic acetylcholine receptor M5

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: antagonist

General Function:: Phosphatidylinositol phospholipase c activity
Specific Function:: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:: CHRM5
Uniprot ID:: P08912
Molecular Weight:: 60073.205 Da

References

Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. [PubMed:10374898 ]
Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909 ]

Enzymes

Details

1. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Vitamin d3 25-hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:: CYP3A4
Uniprot ID:: P08684
Molecular Weight:: 57342.67 Da

References

Skerjanec A: The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50. [PubMed:16584282 ]

Details

2. Cytochrome P450 2D6

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrateinhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:: CYP2D6
Uniprot ID:: P10635
Molecular Weight:: 55768.94 Da

References

Skerjanec A: The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50. [PubMed:16584282 ]

Drug created on June 13, 2005 07:24 / Updated on June 22, 2017 09:57

Get DrugBank to go!

Structure for DB00496 (Darifenacin)

Targets

References

References

References

References

References

Enzymes

References

References